glp 1 coverage bcbs glp-1 GLP-1 Drugs: What Employers Need to Know MCT2D | 2023 Updates to

The bigger message is that these agents are pushing us toward a more integrated cardiometabolic model of care, in which obesity, heart failure, kidney disease, liver disease, and vascular risk are treated as connected biology rather than asseparate silos.

This class of weight-loss drugs is having visible effects not only on the faces and waistlines of []

Charles Barkley may be watching his waistline as the new spokesman for Weight Watchers, but apparently hes not watching his words too closely

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes &amp